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Review criteriaReferences were collected via search on PubMed (terms used alone or together: linagliptin, empagliflozin, dapagliflozin, saxagliptin, combination and type 2 diabetes), 2012--2014 ADA and EASD abstract databases, [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (keywords: linagliptin, empagliflozin, dapagliflozin and saxagliptin), drug manufacturers' websites and references known to the author.Relevant references were identified after screening titles and further analysed based on abstracts.Content was focused on characteristics of empagliflozin and linagliptin, their combinations, and the dapagliflozin/saxagliptin combination.Message for the clinicIn patients with mean baseline HbA1c levels of 8.0%, the empagliflozin/linagliptin combination lowered HbA1c by approximately 1.1% without hypoglycaemia, and reduced mean body weight by 2.0--3.0 kg.The combination offers a suitable component in strategy to achieve target HbA1c without hypoglycaemia and weight gain.The combination did not show any concerning safety findings; patients should be made aware of possibility of genital infections.

Introduction {#ijcp12720-sec-0008}
============

The standard pharmacotherapy for management of type 2 diabetes mellitus (T2DM) involves initiation with monotherapy (usually metformin) unless there are contraindications or intolerance, followed by sequential addition of other single agents, when target glycaemic control is not achieved or maintained for 3 months [1](#ijcp12720-bib-0001){ref-type="ref"}, [2](#ijcp12720-bib-0002){ref-type="ref"}. Combination therapy as first line is a treatment option when glycated haemoglobin (HbA1c) at entry is well above target. The joint position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends initial combination therapy in patients with baseline HbA1c ≥ 9% and who are less likely to achieve treatment goals on monotherapy [1](#ijcp12720-bib-0001){ref-type="ref"}, [2](#ijcp12720-bib-0002){ref-type="ref"}. The American Association of Clinical Endocrinologists' and American College of Endocrinology\'s (AACE/ACE) comprehensive diabetes management algorithm recommends initial dual therapy when HbA1c is ≥ 7.5%, and combination therapy with insulin (symptomatic hyperglycaemia) or without insulin (asymptomatic hyperglycaemia) when HbA1c is ≥ 9% [3](#ijcp12720-bib-0003){ref-type="ref"}. Initial combination therapy potentially offers advantages such as rapid reduction in HbA1c, avoidance of extended periods of hyperglycaemic state and harmful effects of glucotoxicity, and avoidance of maximal doses of monotherapy which may augment adverse effects associated with that monotherapy [4](#ijcp12720-bib-0004){ref-type="ref"}, [5](#ijcp12720-bib-0005){ref-type="ref"}. The strategy also allows for implementation of a multipronged approach for control of hyperglycaemia by use of drugs with complementary mechanisms of action. Combination therapy is aimed at aggressive attainment and maintenance of glycaemic targets. However, aggressive treatment to achieve glycaemic control may not always be suitable depending on the patient and disease characteristics, and therefore, glycaemic targets must be individualised according to the needs of each patient. When the need for combination therapy has been established, drugs with complementary mechanisms of action should be employed for optimum glycaemic control [3](#ijcp12720-bib-0003){ref-type="ref"}.

A common caveat is that combining two or more antihyperglycaemic agents (AHAs) can increase the risk of hypoglycaemia and/or weight gain, particularly if thiazolidinediones, sulfonylureas and/or insulin are used [6](#ijcp12720-bib-0006){ref-type="ref"}, [7](#ijcp12720-bib-0007){ref-type="ref"}. The two relatively recent classes of AHAs -- dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium glucose co‐transporter 2 (SGLT2) inhibitors -- as monotherapies are associated with low incidence of hypoglycaemia and weight neutrality (DPP‐4 inhibitors) or weight loss (SGLT2 inhibitors), and thus can be useful options in a combination. DPP‐4 inhibitors are rapidly replacing sulfonylureas as a second‐line treatment [8](#ijcp12720-bib-0008){ref-type="ref"}. Both DPP‐4 inhibitors and SGLT2 inhibitors are given orally allowing for administration as loose‐pill or single‐tablet combination (STC). Benefits of STCs over loose‐pill combinations in the treatment of T2DM may include improved patient adherence, patient satisfaction and lower overall healthcare costs [9](#ijcp12720-bib-0009){ref-type="ref"}.

Empagliflozin/linagliptin is the first‐in‐class dual inhibitor combination therapy (SGLT2/DPP‐4), recently approved by the US Food and Drug Administration (FDA) [10](#ijcp12720-bib-0010){ref-type="ref"}. The STC is available in two dosage strengths: empagliflozin 10 mg/linagliptin 5 mg and empagliflozin 25 mg/linagliptin 5 mg. According to public information, a new drug application for approval in the USA has been filed for the dapagliflozin/saxagliptin STC [11](#ijcp12720-bib-0011){ref-type="ref"}.

Results of three randomised controlled trials (RCTs) investigating the efficacy and safety of SGLT2/DPP‐4 inhibitor combinations have been reported [12](#ijcp12720-bib-0012){ref-type="ref"}, [13](#ijcp12720-bib-0013){ref-type="ref"}, [14](#ijcp12720-bib-0014){ref-type="ref"}. This review summarises these results and compares the profiles of the SGLT2/DPP‐4 inhibitor combinations. Characteristics of linagliptin and empagliflozin as individual drugs are also discussed.

Methods {#ijcp12720-sec-0009}
=======

A non‐systematic search was conducted on PubMed using the following terms alone or in combination: linagliptin, empagliflozin, dapagliflozin, saxagliptin, combination and type 2 diabetes. Relevant references were identified after screening the titles. Abstract databases for the ADA and EASD spanning the years 2012--2014 were searched using the keywords: linagliptin, empagliflozin, dapagliflozin and saxagliptin. Relevant ongoing studies were identified from [www.clinicaltrials.gov](http://www.clinicaltrials.gov) using the keywords: linagliptin, empagliflozin, dapagliflozin and saxagliptin. Other sources included drug manufacturers' websites, Google Scholar and references known to the author.

Mechanisms of action {#ijcp12720-sec-0010}
====================

The antihyperglycaemic effects of DPP‐4 inhibitors mainly stem from increasing the half‐life of glucagon‐like peptide‐1 (GLP‐1) -- the incretin that is otherwise rapidly degraded by DPP‐4 [15](#ijcp12720-bib-0015){ref-type="ref"}. DPP‐4 is a proteolytic enzyme with several biochemical substrates [16](#ijcp12720-bib-0016){ref-type="ref"}, including GLP‐1 and glucose‐dependent insulinotropic peptide, which play critical roles in blood glucose regulation. GLP‐1 acts primarily by stimulating pancreatic β cells for insulin secretion after meal intake, suppressing glucagon production, delaying gastric emptying and inducing satiety [17](#ijcp12720-bib-0017){ref-type="ref"}. SGLT2 inhibitors promote elimination of excess glucose via urine. SGLT2 is a membrane protein expressed primarily in the S1 segments of the renal proximal tubule. SGLT2 reabsorbs about 90% of the glucose filtered by the kidney [18](#ijcp12720-bib-0018){ref-type="ref"}. In patients with T2DM, the glucose reabsorption capacity of the kidney is increased. This is likely because of over‐expression of SGLT2 and GLUT2, a facilitative glucose transporter [19](#ijcp12720-bib-0019){ref-type="ref"}, [20](#ijcp12720-bib-0020){ref-type="ref"}. SGLT2 inhibition counteracts the excess glucose reabsorption in kidney by blocking the physiological activity of the protein. The excess glucose is then excreted via urine [21](#ijcp12720-bib-0021){ref-type="ref"}.

Metabolic studies in patients with T2DM have shown that SGLT2 inhibition is associated with an increase in endogenous glucose production (EGP), likely as a response to glycosuria [22](#ijcp12720-bib-0022){ref-type="ref"}, [23](#ijcp12720-bib-0023){ref-type="ref"}. In the study with empagliflozin, a single dose of empagliflozin 25 mg in the fasted state led to glycosuria of approximately 8 g/3 h and an increase in EGP of 25% (averaging to 7 g over those 3 h). After meal EGP was also increased relative to baseline \[median area under the curve (AUC), 40 g (interquartile range, IQR 14) vs. 34 g (IQR, 11); p \< 0.01\], although oral glucose appearance was not altered. Increased EGP was, at least partly, because of increased plasma glucagon concentration and decreased insulin concentration, which lowered the plasma insulin/glucagon ratio \[from 9 (IQR, 5) to 7 (IQR, 4) mol/mol, p \< 0.0001 vs. baseline\] [22](#ijcp12720-bib-0022){ref-type="ref"}.

Merovci et al. compared dapagliflozin 10 mg/day with placebo over 2 weeks. On day 2, the mean dapagliflozin minus placebo difference in EGP/4 h (0.76 ± 0.10 mg/kg/min or 16.6 g; p \< 0.05) amounted to glycosuria over those 4 h of approximately 15 g [23](#ijcp12720-bib-0023){ref-type="ref"}. The plasma glucagon/insulin ratio with dapagliflozin on day 14 (mean ± SE, 27 ± 7) was higher than that with placebo (mean ± SE, 8 ± 2). Based on these findings, the investigators postulated that: 'combination therapy with SGLT2 inhibitor plus DPP‐4 inhibitor or GLP‐1 analog would exert an additive or even synergistic effect to lower plasma glucose concentration and HbA1c in individuals with T2DM.'

Given the glucagon‐suppressing [24](#ijcp12720-bib-0024){ref-type="ref"}, [25](#ijcp12720-bib-0025){ref-type="ref"}, [26](#ijcp12720-bib-0026){ref-type="ref"} and insulin‐stimulating effects that have been demonstrated with DPP‐4 inhibition, a DPP‐4 inhibitor co‐administered with an SGLT2 inhibitor could counterbalance -- to some extent -- the decreased plasma insulin/glucagon ratio, and enhance the glucose‐lowering effects of SGLT2 inhibitor treatment.

Linagliptin {#ijcp12720-sec-0011}
===========

The recommended oral dose of linagliptin is 5 mg once daily [27](#ijcp12720-bib-0027){ref-type="ref"}. Linagliptin is mainly excreted non‐renally [28](#ijcp12720-bib-0028){ref-type="ref"}. The efficacy and exposure of linagliptin is not significantly affected by renal impairment [29](#ijcp12720-bib-0029){ref-type="ref"}, and therefore, it can be used without dose adjustment in patients with renal impairment. In addition, although linagliptin is mainly eliminated by a hepatobiliary route, no dose adjustment is recommended in patients with hepatic impairment [27](#ijcp12720-bib-0027){ref-type="ref"}.

In a large clinical trial programme, linagliptin, with or without other antidiabetes drugs, has shown mean reductions in HbA1c ranging from −0.5% to −2.8% [30](#ijcp12720-bib-0030){ref-type="ref"}, [31](#ijcp12720-bib-0031){ref-type="ref"}, [32](#ijcp12720-bib-0032){ref-type="ref"}, [33](#ijcp12720-bib-0033){ref-type="ref"}, [34](#ijcp12720-bib-0034){ref-type="ref"}, [35](#ijcp12720-bib-0035){ref-type="ref"}, [36](#ijcp12720-bib-0036){ref-type="ref"}, [37](#ijcp12720-bib-0037){ref-type="ref"}, [38](#ijcp12720-bib-0038){ref-type="ref"}. In patients with T2DM who are unable to reach the target HbA1c with metformin alone, 24‐week treatment with linagliptin as an add‐on therapy to metformin significantly lowered mean HbA1c by 0.6% relative to placebo [37](#ijcp12720-bib-0037){ref-type="ref"}. Initial dual therapy with linagliptin plus metformin significantly lowered HbA1c after 24 weeks compared with metformin alone (adjusted mean ± SE change from baseline, −1.6 ± 0.1% with linagliptin 2.5 mg plus metformin 1000 mg twice daily vs. −1.1 ± 0.1% with metformin 1000 mg twice daily; treatment difference, −0.5 ± 0.1%, p \< 0.0001) [33](#ijcp12720-bib-0033){ref-type="ref"}. In a 24‐week study comparing initial linagliptin plus metformin treatment with linagliptin monotherapy in newly diagnosed patients with pronounced hyperglycaemia (baseline HbA1c range, ≥ 8.5% to ≤ 12.0%), the adjusted mean ± SE changes in HbA1c were −2.8 ± 0.1% with linagliptin/metformin combination and −2.0 ± 0.1% with linagliptin alone (treatment difference, −0.8%, p* *\<* *0.0001) [36](#ijcp12720-bib-0036){ref-type="ref"}.

In individual trials and pooled analyses, compared with placebo, linagliptin did not increase the risk of hypoglycaemia (except when a sulfonylurea or insulin was used as background therapy), weight gain, pancreatic cancer, acute pancreatitis or cardiovascular adverse events (AEs). Higher incidence rates of hypoglycaemia with linagliptin relative to placebo have been observed when sulfonylurea was used as background therapy [34](#ijcp12720-bib-0034){ref-type="ref"}, [35](#ijcp12720-bib-0035){ref-type="ref"}, [39](#ijcp12720-bib-0039){ref-type="ref"}. A recent comprehensive safety analysis of linagliptin pooled data from 22 randomised, placebo‐controlled trials (*n *=* *7400). In this analysis, pancreatitis occurred at very low and comparable rates in the linagliptin and placebo groups (both \< 0.1%) [39](#ijcp12720-bib-0039){ref-type="ref"}. In the same safety analysis, linagliptin did not increase the incidence of cardiac disorders (including conditions such as coronary artery disease, arrhythmias, heart failure and valve disorders); event rates were low and similar to that of placebo (3.2% and 3.3% of patients in the linagliptin and placebo groups, respectively) [39](#ijcp12720-bib-0039){ref-type="ref"}. Ongoing dedicated cardiovascular and renal outcomes trials with linagliptin in patients with a history of cardiovascular disease or its risk factors, or renal impairment, include CAROLINA^®^ (NCT01243424), CARMELINA^®^ (NCT01897532) and MARLINA‐T2D^™^ (NCT01792518).

The US prescribing information for linagliptin includes a section on postmarketing reports of acute pancreatitis, including fatal pancreatitis in individuals taking linagliptin, and recommends discontinuation if pancreatitis is suspected [27](#ijcp12720-bib-0027){ref-type="ref"}. A recent joint investigation by the FDA and the European Medicines Agency (EMA) concluded that a determination of causality between incretin‐based therapies and pancreatitis or pancreatic cancer is not supported by the available data, and that the product labelling for these drugs is appropriate [40](#ijcp12720-bib-0040){ref-type="ref"}. However, safety signals for pancreatitis will continue to be monitored [40](#ijcp12720-bib-0040){ref-type="ref"}.

Empagliflozin {#ijcp12720-sec-0012}
=============

Empagliflozin is available as 10 and 25 mg tablets. The recommended dose is 10 mg once daily, which can be increased to 25 mg once daily [41](#ijcp12720-bib-0041){ref-type="ref"}. Because of its renal mechanism of action, renal function status affects the use of empagliflozin. Empagliflozin is contraindicated in patients with severe renal impairment, end‐stage renal disease or who are on dialysis. The US prescribing information recommends assessment of renal function prior to initiation of treatment, and that treatment with empagliflozin should not be initiated (or should be discontinued if already being used) if the estimated glomerular filtration rate (eGFR) is less than 45 ml/min/1.73 m^2^ [41](#ijcp12720-bib-0041){ref-type="ref"}.

In phase 3 clinical trials, empagliflozin, with or without other AHAs, has shown glycaemic efficacy (placebo‐corrected mean reduction in HbA1c ranging from −0.5% to −0.9%) without increased risk of hypoglycaemia [42](#ijcp12720-bib-0042){ref-type="ref"}, [43](#ijcp12720-bib-0043){ref-type="ref"}, [44](#ijcp12720-bib-0044){ref-type="ref"}, [45](#ijcp12720-bib-0045){ref-type="ref"}. As 24‐week treatment added on to metformin and a sulfonylurea, empagliflozin significantly lowered HbA1c relative to placebo \[placebo‐adjusted difference (95% confidence interval; CI), −0.6% (−0.8 to −0.5) with empagliflozin 10 mg and --0.6% (−0.7 to −0.5) with empagliflozin 25 mg; both p \< 0.001\] [42](#ijcp12720-bib-0042){ref-type="ref"}. In a head‐to‐head RCT comparing empagliflozin 25 mg/day (*n *=* *796) with glimepiride 1--4 mg/day (*n *=* *780) added to metformin, empagliflozin was non‐inferior to glimepiride in lowering HbA1c at 52 and 104 weeks [44](#ijcp12720-bib-0044){ref-type="ref"}. At 104 weeks, the glimepiride adjusted mean difference in HbA1c change with empagliflozin was −0.1% (−0.2 to −0.02); p \< 0.0001. Overall AEs occurred at similar rates between groups, while the rates of serious adverse events (SAEs) were slightly higher with empagliflozin (16%) than with glimepiride (11%), with 4% of patients in the empagliflozin group and 25% of patients in the glimepiride group having experienced hypoglycaemia [44](#ijcp12720-bib-0044){ref-type="ref"}.

In clinical trials, treatment with empagliflozin, as with other SGLT2 inhibitors, has been shown to reduce body weight (placebo/active comparator‐corrected mean reductions, −1.76 to −4.5 kg) [42](#ijcp12720-bib-0042){ref-type="ref"}, [43](#ijcp12720-bib-0043){ref-type="ref"}, [44](#ijcp12720-bib-0044){ref-type="ref"}, [45](#ijcp12720-bib-0045){ref-type="ref"}. This observation is likely because of caloric loss following glycosuria. In a meta‐analysis of RCTs (10 trials, *n *=* *6203), empagliflozin 25 mg showed a significant reduction in body weight \[weighted mean difference; WMD (95% CI), −1.84 kg (−2.30 to −1.38)\] and no increased risk of hypoglycaemia \[odds ratio; OR (95% CI), 1.10 (0.87--1.39)\] vs. placebo [46](#ijcp12720-bib-0046){ref-type="ref"}.

In a 12‐week study in patients with T2DM and hypertension \[*n *=* *825; mean seated systolic blood pressure (SBP) 130--159 mmHg and diastolic blood pressure (DBP) 80--99 mmHg\], empagliflozin elicited significant changes in blood pressure relative to placebo \[difference vs. placebo in mean 24‐h SBP (95% CI), −3.44 mmHg (−4.78 to −2.09) with 10 mg and −4.16 mmHg (−5.50 to −2.83) with 25 mg; DBP (95% CI), −1.36 mmHg (−2.15 to −0.56) with 10 mg and −1.72 mmHg (−2.51 to −0.93) with 25 mg\]. The investigators suggested that empagliflozin maintained the variations in blood pressure according to the circadian clock, as the reductions in daytime SBP and DBP were greater than those at night. Adjusted mean differences vs. placebo in HbA1c were −0.6% (95% CI, −0.7 to −0.5) with empagliflozin 10 mg and −0.7% (95% CI, −0.8 to −0.6) with empagliflozin 25 mg (both p \< 0.001) [47](#ijcp12720-bib-0047){ref-type="ref"}. Similarly, in the meta‐analysis, empagliflozin 25 mg showed positive effects on SBP \[WMD (95% CI), −4.19 mmHg (−5.17 to −3.20)\] vs. placebo [46](#ijcp12720-bib-0046){ref-type="ref"}. Empagliflozin has also been shown to reduce plasma uric acid levels. In a pooled analysis of four pivotal phase 3 trials, empagliflozin 10 mg and 25 mg significantly reduced uric acid compared with placebo at week 24 \[placebo‐corrected mean (SE) changes, −28.95 (1.82) μmol/l and −29.55 (1.83) μmol/l, respectively; both p \< 0.001\] [48](#ijcp12720-bib-0048){ref-type="ref"}.

The US prescribing information for empagliflozin indicates that female genital mycotic infections and urinary tract infections (UTIs) are the most common AEs associated with the drug [41](#ijcp12720-bib-0041){ref-type="ref"}. In the meta‐analysis, the incidence of UTIs did not increase with empagliflozin 10 or 25 mg relative to placebo \[ORs (95% CI), 1.20 (0.92--1.57) and 1.03 (0.81 to 1.32)\] [46](#ijcp12720-bib-0046){ref-type="ref"}. However, genital infections were observed in a greater proportion of patients treated with empagliflozin than in those receiving placebo \[ORs (95% CI), 4.39 (2.10--9.19) with 10 mg and 3.31 (1.55--7.09) with 25 mg\] [46](#ijcp12720-bib-0046){ref-type="ref"}.

Empagliflozin causes osmotic diuresis, which can lead to adverse effects associated with volume depletion (dehydration, hypotension, hypovolaemia, orthostatic hypotension and syncope). Assessment and correction of volume depletion is recommended before initiating empagliflozin treatment [41](#ijcp12720-bib-0041){ref-type="ref"}. Lipid changes with empagliflozin have not been consistently observed. While a clinical impact is not yet clear, patients on empagliflozin should be monitored for lipid changes. A large cardiovascular outcomes trial (*n *=* *7034) in patients with T2DM and a heightened risk of cardiovascular disease is investigating the long‐term cardiovascular safety profile and the potential cardiovascular protective effects of empagliflozin [49](#ijcp12720-bib-0049){ref-type="ref"}.

SGLT2/DPP‐4 inhibitor STCs {#ijcp12720-sec-0013}
==========================

Efficacy {#ijcp12720-sec-0014}
--------

A pharmacokinetics study of empagliflozin and linagliptin dosed together revealed that there were no drug--drug pharmacokinetic interactions [50](#ijcp12720-bib-0050){ref-type="ref"}. The overall drug exposure (AUC) and peak drug concentration (*C* ~max~) for both drugs remained unaffected after co‐administration, indicating that they can be used in combination without dose adjustment. Data from clinical studies with empagliflozin/linagliptin and dapagliflozin/saxagliptin combinations are emerging. Results of three phase 3 RCTs, which compared the combinations with corresponding monotherapies, have been reported to date [12](#ijcp12720-bib-0012){ref-type="ref"}, [13](#ijcp12720-bib-0013){ref-type="ref"}, [14](#ijcp12720-bib-0014){ref-type="ref"}. Baseline characteristics of these study populations are shown in Table [1](#ijcp12720-tbl-0001){ref-type="table-wrap"}. While all three studies were comparable with respect to study size, mean baseline age, body mass index and gender distribution, the mean HbA1c at baseline in the dapagliflozin/saxagliptin study was higher than in the empagliflozin/linagliptin studies (Table [1](#ijcp12720-tbl-0001){ref-type="table-wrap"}). The inclusion/exclusion criteria allowed patients with a baseline HbA1c ranging from \> 7% to ≤ 10.5% in the two empagliflozin/linagliptin studies and from ≥ 8% to ≤ 12.0% in the dapagliflozin/saxagliptin study.

###### 

Completed phase 3 RCTs with DDP‐4i/SGLT2i combinations

  Combination                                                                            Duration (weeks)   *N* [\*](#ijcp12720-note-0002){ref-type="fn"}   Background therapy   Baseline characteristics                         
  -------------------------------------------------------------------------------------- ------------------ ----------------------------------------------- -------------------- -------------------------- -------- ------------ ------------------------------------------------------------------
  Empagliflozin 25 or 10 mg/linagliptin 5 mg [13](#ijcp12720-bib-0013){ref-type="ref"}   52                 677                                             None                 54.6 (10.2)                49--58   31.6 (5.6)   7.99 (0.97)--8.05 (1.03)[‡](#ijcp12720-note-0002){ref-type="fn"}
  Empagliflozin 25 or 10 mg/linagliptin 5 mg [12](#ijcp12720-bib-0012){ref-type="ref"}   52                 686                                             Metformin            56.2 (10.2)                46--62   31.0 (5.5)   7.90 (0.79)--8.02 (0.90)[‡](#ijcp12720-note-0002){ref-type="fn"}
  Dapagliflozin 10 mg/saxagliptin 5 mg [14](#ijcp12720-bib-0014){ref-type="ref"}         24                 534                                             Metformin            54 (10)                    50       31.7 (5.1)   8.94 (1.13)[†](#ijcp12720-note-0002){ref-type="fn"}

RCTs, randomised controlled trials; DPP‐4i, dipeptidyl peptidase‐4 inhibitors; SGLT2i, sodium glucose co‐transporter 2 inhibitors. \*Number of patients randomised. ^†^Data are mean (SD). ^‡^Data are mean (SD) and represent the range across all treatment arms.
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In a 52‐week study in drug‐naïve patients, both empagliflozin 10 mg/linagliptin 5 mg (E10/L5) and empagliflozin 25 mg/linagliptin 5 mg (E25/L5) STCs were compared with their respective monotherapy components [13](#ijcp12720-bib-0013){ref-type="ref"}. At 24 weeks, adjusted mean (SE) reductions from baseline were −1.08% (0.06) with E25/L5 \[mean (SD) baseline, 7.99% (0.95)\] and −1.24% (0.06) with E10/L5 \[mean (SD) baseline, 8.04% (0.96)\]. Both STCs significantly reduced mean HbA1c, fasting plasma glucose (FPG) and body weight relative to L5 alone (Table [2](#ijcp12720-tbl-0002){ref-type="table-wrap"}) [13](#ijcp12720-bib-0013){ref-type="ref"}. Compared with E10 mono‐treatment, E10/L5 STC showed a significant adjusted mean difference in HbA1c, but not in FPG or body weight (Table [2](#ijcp12720-tbl-0002){ref-type="table-wrap"}). Adjusted mean differences between E25/L5 STC vs. E25 did not achieve statistical significance for HbA1c, FPG or body weight. Higher proportions of patients achieved HbA1c \< 7% with the STCs (55.4% and 62.3% with E25/L5 and E10/L5, respectively) than their respective monotherapy components (41.5%, 38.8% and 32.3% with E25, E10 and L5, respectively).

###### 

Primary and key secondary end‐points at 24 weeks with empagliflozin/linagliptin STCs in drug‐naïve patients [13](#ijcp12720-bib-0013){ref-type="ref"}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           E25/L5 STC                                                                                                      E10/L5 STC
  ---------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  *N*                                      134                                                                                                             135

  **HbA1c (%)**                                                                                                                                            

  Baseline                                 7.99 (0.95)[\*](#ijcp12720-note-0003){ref-type="fn"}                                                            8.04 (0.96)[\*](#ijcp12720-note-0003){ref-type="fn"}

  Change from baseline                     −1.08 (0.06)[†](#ijcp12720-note-0003){ref-type="fn"}                                                            −1.24 (0.06)[†](#ijcp12720-note-0003){ref-type="fn"}

  Difference vs. mono‐treatment (95% CI)   −0.14 (−0.33, 0.06) vs. E25\                                                                                    −0.41 (−0.61, −0.21)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. E10\
                                           −0.41 (−0.61, −0.22)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5                                             −0.57 (−0.76, −0.37)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5

  **Patients with HbA1c \< 7% (%)**        55.4                                                                                                            62.3

  Difference vs. mono‐treatment (95% CI)   1.89[§,¶](#ijcp12720-note-0003){ref-type="fn"} (1.1, 3.3)[\*\*](#ijcp12720-note-0003){ref-type="fn"} vs. E25\   2.96[§,¶](#ijcp12720-note-0003){ref-type="fn"} (1.7, 5.2)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. E10\
                                           3.1[§,¶](#ijcp12720-note-0003){ref-type="fn"} (1.8, 5.3)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5         4.3[§,¶](#ijcp12720-note-0003){ref-type="fn"} (2.5, 7.5)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5

  **FPG (mg/dl)**                                                                                                                                          

  Baseline                                 156.1 (35.8)[\*](#ijcp12720-note-0003){ref-type="fn"}                                                           157.2 (35.4)[\*](#ijcp12720-note-0003){ref-type="fn"}

  Change from baseline                     −29.6 (2.7)                                                                                                     −28.2 (2.7)

  Difference vs. mono‐treatment (95% CI)   −5.3 (−12.7, 2.1) vs. E25\                                                                                      −5.8 (−13.3, 1.6) vs. E10\
                                           −23.6 (−31.1, −16.2)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5                                             −22.3 (−29.7, −14.9)[¶](#ijcp12720-note-0003){ref-type="fn"} vs. L5

  **Body weight (kg)**                                                                                                                                     

  Baseline                                 87.9 (18.2)[\*](#ijcp12720-note-0003){ref-type="fn"}                                                            87.3 (18.4)[\*](#ijcp12720-note-0003){ref-type="fn"}

  Change from baseline                     −2.0 (0.4)                                                                                                      −2.7 (0.4)

  Difference vs. mono‐treatment (95% CI)   0.1 (−0.9, 1.1) vs. E25\                                                                                        −0.5 (−1.5, 0.5) vs. E10\
                                           −1.2 (−2.2, −0.2)[\*](#ijcp12720-note-0003){ref-type="fn"} vs. L5                                               −2.0 (−3.0, −1.0)‡ vs. L5
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

STC, single‐tablet combination; E25, empagliflozin 25 mg; E10, empagliflozin 10 mg; L5, linagliptin 5 mg. \*Data are mean (SD) in the full analysis set (patients who received ≥ 1 dose of the study drug and had baseline and ≥1 HbA1c measurement after treatment). ^†^Data are adjusted mean (SE) analysed using analysis of covariance (ANCOVA) model on the full analysis set using last observation carried forward (LOCF) method for imputation of missing values. ^§^Values are odds ratios for combination vs. the respective mono‐treatments. ^¶^p \< 0.001. \*\*p \< 0.05.

John Wiley & Sons, Ltd

Glycaemic efficacy of the empagliflozin/linagliptin STCs were maintained over 52 weeks. Relative to L5 alone, E25/L5 and E10/L5 achieved significant adjusted mean differences in HbA1c \[−0.66% (−0.90, −0.43) and −0.71% (−0.94, −0.48), respectively; both p \< 0.001\]. Similarly, significant mean differences in HbA1c were observed with E10/L5 vs. E10, but not with E25/L5 vs. E25 [13](#ijcp12720-bib-0013){ref-type="ref"}. Mean differences in body weight and FPG at 52 weeks with the STCs were significant vs. L5 alone, but not vs. the respective empagliflozin monotherapy components. No significant treatment differences in changes from baseline in SBP and DBP were observed.

Empagliflozin/linagliptin and dapagliflozin/saxagliptin combinations have also been evaluated in patients taking metformin as background therapy. Both empagliflozin/linagliptin STCs -- E25/L5 and E10/L5 taken once daily resulted in significant mean differences in HbA1c and FPG compared with the respective mono‐treatments after 24 weeks (Table [3](#ijcp12720-tbl-0003){ref-type="table-wrap"}) [12](#ijcp12720-bib-0012){ref-type="ref"}. Higher proportions of patients achieved HbA1c \< 7% with E25/L5 (61.8%) and E10/L5 STCs (57.8%) than with their respective mono‐treatments (32.6%, 28.0% and 36.1% with E25, E10 and L5, respectively). Mean differences in body weight with the empagliflozin/linagliptin STCs were significant vs. linagliptin mono‐treatment but not vs. the two empagliflozin mono‐treatments. Glycaemic efficacy of the empagliflozin/linagliptin STCs was maintained over 52 weeks. Adjusted mean differences in SBP and DBP at 52 weeks were significant between the STCs and linagliptin alone \[−3.8 mmHg (−6.5, −1.2) and −1.6 mmHg (−3.2, 0) with E25/L5; --3.1 mmHg (−5.7, −0.4) and −1.6 mmHg (−3.2, 0) with E10/L5\], but not between the STCs and the empagliflozin mono‐treatments.

###### 

Primary and key secondary end‐points at 24 weeks with empagliflozin/linagliptin and dapagliflozin/saxagliptin combinations in patients on metformin background therapy [12](#ijcp12720-bib-0012){ref-type="ref"}, [14](#ijcp12720-bib-0014){ref-type="ref"}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                E25/L5 STC                                                                                                      E10/L5 STC                                                                                                      D10/S5 LPC
  ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  *N*                                                           134                                                                                                             135                                                                                                             176

  **HbA1c (%)**                                                                                                                                                                                                                                                                                 

  Baseline                                                      7.90 (0.79)[\*](#ijcp12720-note-0004){ref-type="fn"}                                                            7.95 (0.80)[\*](#ijcp12720-note-0004){ref-type="fn"}                                                            8.93 ± 1.19[\*](#ijcp12720-note-0004){ref-type="fn"}

  Change from baseline                                          −1.19 (0.06)[†](#ijcp12720-note-0004){ref-type="fn"}                                                            −1.08 (0.06)[†](#ijcp12720-note-0004){ref-type="fn"}                                                            −1.47 (0.08)[†](#ijcp12720-note-0004){ref-type="fn"}

  Difference vs. mono‐treatment (95% CI)                        −0.58 (−0.75, −0.41)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. E25\                                           −0.42 (−0.59, −0.25)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. E10\                                           −0.27 (−0.48, −0.05)[§](#ijcp12720-note-0004){ref-type="fn"} vs. D10\
                                                                −0.50 (−0.67, −0.32)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                             −0.39 (−0.56, −0.21)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                             −0.59 (−0.81, −0.37)[¶](#ijcp12720-note-0004){ref-type="fn"} vs. S5

  **Patients with HbA1c \< 7% (** ***n*** **/** ***N*** **)**   76/123                                                                                                          74/128                                                                                                          74/177

  Difference vs. mono‐treatment (95% CI)                        4.19[\*\*](#ijcp12720-note-0004){ref-type="fn"} (2.32, 7.57)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. E25\   4.50[\*\*](#ijcp12720-note-0004){ref-type="fn"} (2.47, 8.18)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. E10\   19[††](#ijcp12720-note-0004){ref-type="fn"} (10.1, 28.1) vs. D10\
                                                                3.50[\*\*](#ijcp12720-note-0004){ref-type="fn"} (1.92, 6.36)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5     2.80[\*\*](#ijcp12720-note-0004){ref-type="fn"} (1.56, 5.00)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5     23[††](#ijcp12720-note-0004){ref-type="fn"} (14.7, 31.5) vs. S5

  **FPG (mg/dl)**                                                                                                                                                                                                                                                                               

  Baseline                                                      154.6 (33.3)[\*](#ijcp12720-note-0004){ref-type="fn"}                                                           156.7 (34.4)[\*](#ijcp12720-note-0004){ref-type="fn"}                                                           186 ± 46.6[\*](#ijcp12720-note-0004){ref-type="fn"}

  Change from baseline                                          −35.3                                                                                                           −32.2                                                                                                           −38.0 (−43.2, −32.3)

  Difference vs. mono‐treatment (95% CI)                        −16.4 (−23.4, −9.5)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. E25\                                            −11.3 (−18.3, −4.4)[‡‡](#ijcp12720-note-0004){ref-type="fn"} vs. E10\                                           −6.0 (−13.8, 1.7) vs. D10\
                                                                −22.2 (−29.3, −15.1)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                             −19.1 (−26.2, −12.0)[‡](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                             −24.0 (−31.6, −15.9) vs. S5

  **Body weight (kg)**                                                                                                                                                                                                                                                                          

  Baseline                                                      85.5 (20.4)                                                                                                     86.6 (19.0)                                                                                                     87.1 ± 18.0

  Change from baseline                                          −3.0                                                                                                            −2.6                                                                                                            −2.1 (−2.5, −1.6)

  Difference vs. mono‐treatment (95% CI)                        0.2 (−0.7, 1.0) vs. E25\                                                                                        0.1 (−0.9, 0.8) vs. E10\                                                                                        NR vs. D10\
                                                                −2.3 (−3.2, −1.4)[††](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                               −1.9 (−2.8, −1.1)[††](#ijcp12720-note-0004){ref-type="fn"} vs. L5                                               −2.1 (−2.7, −1.4) vs. S5
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are %. E25, empagliflozin 25 mg; E10, empagliflozin 10 mg; L5, linagliptin 5 mg; D10, dapagliflozin 10 mg; S5, saxagliptin 5 mg; STC, single‐tablet combination; LPC, loose‐pill combination. \*Values are mean (SD). ^†^Values are mean (SE) analysed using analysis of covariance (ANCOVA) model on the full analysis set using last observation carried forward (LOCF) method for imputation of missing values. ^‡^p \< 0.001. ^§^p \< 0.0001. ^¶^p = 0.0166. \*\*Values are odds ratios for combination vs. the respective mono‐treatments. ^††^p \< 0.01. ^‡‡^p \< 0.002.

John Wiley & Sons, Ltd

In patients on metformin, 24‐week treatment with the dapagliflozin 10 mg/saxagliptin 5 mg (D10/S5) combination significantly reduced HbA1c compared with the respective mono‐treatments (Table [3](#ijcp12720-tbl-0003){ref-type="table-wrap"}) [14](#ijcp12720-bib-0014){ref-type="ref"}. Adjusted mean (SE) change in HbA1c was −1.47% (0.08) \[mean (SD) baseline, 8.93% (1.19)\]. Mean ± SE changes in FPG were −38 ± 2.8, −14 ± 2.9 and −32 ± 2.8 mg/dl with the D10/S5 combination, saxagliptin mono‐treatment and dapagliflozin mono‐treatment, respectively. Higher proportions of patients achieved HbA1c \< 7% with D10/S5 (41%) than with the mono‐treatments (18% and 22% with S5 and D10, respectively). Body weight reductions with the combination and dapagliflozin mono‐treatment were comparable; saxagliptin mono‐treatment did not change the mean body weight (Table [3](#ijcp12720-tbl-0003){ref-type="table-wrap"}). In this study, change in blood pressure was part of the safety assessment. At 24 weeks, overall mean reductions in SBP were observed with D10/S5 combination (−1.9 mmHg) and D10 mono‐treatment (−3.5 mmHg). Slight reductions in DBP were seen across all treatment groups (−1.0, −0.4 and −1.4 mmHg with D10/S5, S5 and D10, respectively).

Safety {#ijcp12720-sec-0015}
------

In the empagliflozin/linagliptin STC study in drug‐naïve patients, rates of overall AEs and drug‐related AEs were similar across all groups (Table [4](#ijcp12720-tbl-0004){ref-type="table-wrap"}) [13](#ijcp12720-bib-0013){ref-type="ref"}. No patients in the STC groups experienced confirmed hypoglycaemic events, and rates of such events were low in the mono‐treatment groups. Events consistent with UTIs were observed in similar proportions of patients across all groups, and occurred more frequently in women; none led to treatment discontinuation. Events consistent with genital infections occurred at similar rates in all groups, but two patients who had genital infections discontinued treatment (one in the E25/L5 group and one in the E10 group). At the follow‐up visit -- 4 weeks after the last dose -- modest changes in eGFR ranging from 1.5 ± 11.5 to 4.0 ± 11.7 ml/min/1.73 m^2^ were reported. Both the STCs and empagliflozin mono‐treatments decreased uric acid (−56.5 to −71.4 μmol/l), whereas linagliptin mono‐treatment slightly increased uric acid levels from baseline (3.0 μmol/l). No incidence of worsening of heart failure or hospitalisation because of heart failure was reported.

###### 

Safety profiles of empagliflozin/linagliptin STCs at 52 weeks in drug‐naïve patients and in patients on metformin background therapy [12](#ijcp12720-bib-0012){ref-type="ref"}, [13](#ijcp12720-bib-0013){ref-type="ref"}

                                                  E25/L5 STC   E10/L5 STC   E25          E10          L5
  ----------------------------------------------- ------------ ------------ ------------ ------------ -----------
  **Drug‐naïve patients**                                                                             
  *N* [\*](#ijcp12720-note-0005){ref-type="fn"}   136          136          135          135          135
  Overall AEs                                     103 (75.7)   99 (72.8)    93 (68.9)    110 (81.5)   97 (71.9)
  Serious AEs                                     6 (4.4)      7 (5.1)      9 (6.7)      10 (7.4)     2 (1.5)
  Drug‐related AEs                                23 (16.9)    14 (10.3)    22 (16.3)    16 (11.9)    17 (12.6)
  AEs leading to discontinuation                  9 (6.6)      8 (5.9)      5 (3.7)      7 (5.20)     2 (1.5)
  Hypoglycaemia                                   0            0            1 (0.7)      4 (3.0)      1 (0.7)
  AEs consistent with urinary tract infections    17 (12.5)    21 (15.4)    14 (10.4)    22 (16.3)    14 (10.4)
  AEs consistent with genital infections          8 (5.9)      4 (2.9)      6 (4.4)      7 (5.2)      4 (3.0)
  AEs consistent with volume depletion            1 (0.7)      3 (2.2)      0            0            0
  **Patients on metformin**                                                                           
  *N* [\*](#ijcp12720-note-0005){ref-type="fn"}   134          135          140          137          128
  Overall AEs                                     98 (71.5)    94 (69.1)    103 (73.0)   96 (68.6)    91 (68.9)
  Serious AEs                                     6 (4.4)      9 (6.6)      10 (7.1)     6 (4.3)      8 (6.1)
  Drug‐related AEs                                18 (13.1)    23 (16.9)    26 (18.4)    26 (18.6)    15 (11.4)
  AEs leading to discontinuation                  3 (2.2)      2 (1.5)      4 (2.8)      9 (6.4)      4 (3.0)
  Hypoglycaemia                                   5 (3.6)      3 (2.2)      5 (3.5)      2 (1.4)      3 (2.3)
  AEs consistent with urinary tract infections    14 (10.2)    13 (9.6)     19 (13.5)    16 (11.4)    20 (15.2)
  AEs consistent with genital infections          3 (2.2)      8 (5.9)      12 (8.5)     11 (7.9)     3 (2.3)
  AEs consistent with volume depletion            1 (0.7)      2 (1.5)      2 (1.4)      1 (0.7)      4 (3.0)

E25, empagliflozin 25 mg; E10, empagliflozin 10 mg; L5, linagliptin 5 mg; D10, dapagliflozin 10 mg; S5, saxagliptin 5 mg; STC, single‐tablet combination. \*Treated set, patients who received ≥ 1 doses of the treatment.

John Wiley & Sons, Ltd

In the empagliflozin/linagliptin study in patients taking metformin, frequencies of overall AEs, SAEs, drug‐related AEs and AEs leading to discontinuation were comparable across all groups (Table [4](#ijcp12720-tbl-0004){ref-type="table-wrap"}) [12](#ijcp12720-bib-0012){ref-type="ref"}. Confirmed hypoglycaemia occurred at low rates across all groups, with none of individuals who had a hypoglycaemic event needing assistance. Events consistent with UTIs occurred at comparable rates across all groups; one patient in the E10 group experienced severe urosepsis needing hospitalisation and discontinued treatment. Proportions of patients experiencing events consistent with genital infection were comparable between groups. Two patients in the E25/L5 group with genital infections discontinued treatment. Mean (SD) changes in eGFR at follow‐up ranged from −0.5 (13.0) to 4.8 (13.7) ml/min/1.73 m^2^. No incidence of worsening of heart failure or hospitalisation because of heart failure was reported. Both STCs and empagliflozin mono‐treatments reduced mean uric acid levels relative to the baseline (−45.2 to −63.6 μmol/l), whereas linagliptin mono‐treatment caused a slight increase (9.5 μmol/l).

Among treatment‐naïve patients, mean differences in total cholesterol and high‐density cholesterol (HDL) were significant between E25/L5 STC and L5 mono‐treatments, but not for any other comparisons (Table [5](#ijcp12720-tbl-0005){ref-type="table-wrap"}) [13](#ijcp12720-bib-0013){ref-type="ref"}. No significant between‐group differences were noted in change in low‐density cholesterol (LDL) and triglycerides. Similarly, in patients on metformin background therapy, mean differences in HDL were significant between both the STC groups and linagliptin mono‐treatment. However, no significant between‐group differences were reported for other lipid parameters, including total cholesterol, LDL and triglycerides [12](#ijcp12720-bib-0012){ref-type="ref"}.

###### 

Lipid profile of empagliflozin/linagliptin STCs at 52 weeks in drug‐naïve patients and in patients on metformin background therapy [12](#ijcp12720-bib-0012){ref-type="ref"}, [13](#ijcp12720-bib-0013){ref-type="ref"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                  Drug‐naïve patients           Patients on metformin                                      
  ----------------------------------------------- ----------------------------- ----------------------------- ---------------------------- -----------------------------
  *N* [\*](#ijcp12720-note-0006){ref-type="fn"}   136                           136                           134                          135

  **Total cholesterol (mmol/l)**                                                                                                           

  Baseline                                        5.0 ± 0.1                     5.1 ± 0.1                     4.6 ± 0.1                    4.6 ± 0.1

  Change from baseline                            0.1 ± 0.1                     0.0 ± 0.1                     0.2 ± 0.1                    0.1 ± 0.1

  Difference vs. mono‐treatment (p‐value)         −0.1 ± 0.1 vs. E25 (0.443)\   −0.1 ± 0.1 vs. E10 (0.164)\   0.0 ± 0.1 vs. E25 (0.803)\   −0.1 ± 0.1 vs. E10 (0.478)\
                                                  0.2 ± 0.1 vs. L5 (0.036)      0.1 ± 0.1 vs. L5 (0.135)      0.1 ± 0.1 vs. L5 (0.264)     0.1 ± 0.1 vs. L5 (0.596)

  **HDL cholesterol (mmol/l)**                                                                                                             

  Baseline                                        1.2 ± 0.0                     1.1 ± 0.0                     1.2 ± 0.0                    1.2 ± 0.0

  Change from baseline                            0.1 ± 0.0                     0.1 ± 0.0                     0.1 ± 0.0                    0.1 ± 0.0

  Difference vs. mono‐treatment                   0.0 ± 0.0 vs. E25 (0.126)\    0.0 ± 0.0 vs. E10 (0.507)\    0.0 ± 0.0 vs. E25 (0.564)\   0.0 ± 0.0 vs. E10 (0.890)\
                                                  0.1 ± 0.0 vs. L5 (0.004)      0.1 ± 0.0 vs. L5 (\< 0.001)   0.1 ± 0.0 vs. L5 (0.003)     0.0 ± 0.0 vs. L5 (0.052)

  **LDL cholesterol (mmol/l)**                                                                                                             

  Baseline                                        2.9 ± 0.1                     3.0 ± 0.1                     2.6 ± 0.1                    2.5 ± 0.1

  Change from baseline                            0.0 ± 0.1                     −1.0 ± 0.1                    0.1 ± 0.1                    0.0 ± 0.1

  Difference vs. mono‐treatment (p‐value)         0.0 ± 0.1 vs. E25 (0.759)\    −0.1 ± 0.1 vs. E10 (0.355)\   0.0 ± 0.1 vs. E25 (0.965)\   −0.1 ± 0.1 vs. E10 (0.555)\
                                                  0.1 ± 0.1 vs. L5 (0.155)      0.0 ± 0.1 vs. L5 (0.639)      0.1 ± 0.1 vs. L5 (0.391)     0.0 ± 0.1 vs. L5 (0.712)

  **Triglycerides (mmol/l)**                                                                                                               

  Baseline                                        2.0 ± 0.1                     2.1 ± 0.1                     1.7 ± 0.1                    1.8 ± 0.1

  Change from baseline                            −0.1 ± 0.1                    0.0 ± 0.1                     −0.1 ± 0.1                   0.0 ± 0.1

  Difference vs. mono‐treatment (p‐value)         0.0 ± 0.1 vs. E25 (0.905)\    −0.2 ± 0.1 vs. E10 (0.227)\   0.0 ± 0.1 vs. E25 (0.967)\   −0.1 ± 0.1 vs. E10 (0.596)\
                                                  0.1 ± 0.1 vs. L5 (0.534)      0.1 ± 0.1 vs. L5 (0.292)      −0.1 ± 0.1 vs. L5 (0.271)    0.0 ± 0.1 vs. L5 (0.897)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are mean ± SE analysed using analysis of covariance (ANCOVA) model with treatment, region and eGFR at baseline as fixed effects and baseline HbA1c and baseline end‐point value as linear covariates. \*Treated set. HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; STC, single‐tablet combination; E25, empagliflozin 25 mg; E10, empagliflozin 10 mg; L5, linagliptin 5 mg.

John Wiley & Sons, Ltd

With the dapagliflozin/saxagliptin combination (D10/S5), overall AEs occurred in 49% (87/179) of patients, and the proportion was comparable with the respective mono‐treatments. Hypoglycaemia rates were low (1%) across all treatment groups. UTIs occurred in one patient, whereas none suffered from genital infections. In the D10/S5 combination group, one patient discontinued study participation because of a decreased eGFR.

Ongoing clinical trials with SGLT2/DPP‐4 inhibitor combinations {#ijcp12720-sec-0016}
---------------------------------------------------------------

For patients in whom a dual therapy with either metformin and linagliptin or metformin and empagliflozin does not achieve the glycaemic treatment goal, a third AHA is necessary. Clinical trials designed to investigate addition of a third agent in such populations are currently underway. NCT01778049 is a Phase 3 RCT being conducted in patients with insufficient glycaemic control on metformin monotherapy, who were treated with empagliflozin 10 or 25 mg plus metformin for 16 weeks. Patients not reaching glycaemic goals were then randomised to linagliptin or placebo. This study is comparing the efficacy and safety of linagliptin 5 mg, administered as an STC with empagliflozin 25 or 10 mg, against placebo over 24 weeks in this patient population. Another study, NCT01734785, is a Phase 3 RCT being conducted in patients with insufficient glycaemic control on metformin monotherapy, who were treated with linagliptin 5 mg plus metformin for 16 weeks. Patients not reaching glycaemic goals were then randomised to empagliflozin 10 mg, empagliflozin 25 mg or placebo. This study is comparing the efficacy and safety of empagliflozin 10 and 25 mg, administered as an STC with linagliptin 5 mg, against placebo over 24 weeks in this patient population. Similarly, phase 3 RCTs investigating dapagliflozin 10 mg as an add‐on treatment to saxagliptin 5 mg plus metformin (NCT01646320) and saxagliptin 5 mg as an add‐on treatment to dapagliflozin 10 mg plus metformin (NCT01619059) are currently in progress.

Discussion {#ijcp12720-sec-0017}
==========

Most patients with T2DM will reach a point at which they need a combination of AHAs to achieve and maintain glycaemic targets. Metformin retains its place as first‐line therapy for the treatment of T2DM, but for second‐ and third‐line treatments, medication choices are variable depending on individual patient characteristics. Risk of hypoglycaemia and weight gain are two main side effects of AHAs, which can be compounded by poly‐pharmaceutical approaches. Dual inhibitor combination therapy (SGLT2/DPP‐4) with empagliflozin and linagliptin offers the potential for weight loss and moderate reductions in blood pressure, as well as reduced blood glucose without increased risk of hypoglycaemia. When metformin alone does not reach or maintain glycaemic targets, physicians might consider linagliptin plus metformin or empagliflozin plus metformin fixed‐dose combinations before progressing to triple therapy with metformin plus empagliflozin/linagliptin STC. However, depending on the severity of hyperglycaemia, simultaneous addition of both drugs to metformin background might be appropriate. Phase 3 studies with SGLT2/DPP‐4 dual inhibitor combination therapy in patients taking metformin have demonstrated HbA1c reductions from baseline without an excessive risk of hypoglycaemia.

When metformin is not a suitable option, insulin and GLP‐1 receptor agonists may also be considered. However, patient aversion to injectable therapies must be overcome. In cases of severe hyperglycaemia, dual inhibitor combination therapy added to insulin may help patients to achieve control without the increased risk of hypoglycaemia or weight gain that accompanies escalating the dose of insulin. Although there is no direct clinical evidence supporting use of empagliflozin/linagliptin combination along with insulin, the current data on efficacy and safety of the individual drugs plus insulin make this an intriguing treatment regimen [38](#ijcp12720-bib-0038){ref-type="ref"}, [51](#ijcp12720-bib-0051){ref-type="ref"}. In a RCT (≥ 52 weeks duration), 24‐week treatment with linagliptin 5 mg/day added on to basal insulin caused a greater reduction in HbA1c than placebo \[mean (SD), −0.58% (0.08) and 0.07% (0.08), respectively\] \[treatment difference (95% CI), −0.65% (−0.74, −0.55); p \< 0.0001\] [38](#ijcp12720-bib-0038){ref-type="ref"}. The efficacy was maintained for up to 76 weeks. At week 52, daily insulin dose was increased to a greater extent in the placebo group than in the linagliptin group \[mean (SD) changes, 4.2 (0.8) IU and 2.6 (0.8) IU, respectively; p \< 0.003\]. Notably, the addition of linagliptin did not cause an increase in body weight (mean change −0.3 kg and −0.04 kg with placebo at 52 weeks). The rates of investigator‐defined hypoglycaemia were 31.4% with linagliptin and 32.9% with placebo, although a higher proportion of patients in the placebo group (50.4%) than in the linagliptin group (38.2%) received rescue therapy. Empagliflozin treatment in obese patients with insufficient glycaemic control despite multiple daily injections of insulin lowered HbA1c relative to placebo (at week 18, placebo‐corrected mean ± SE reductions were −0.44 ± 0.08 with 10 mg and −0.52 ± 0.07 with 25 mg \[both p \< 0.001\]) [51](#ijcp12720-bib-0051){ref-type="ref"}. Empagliflozin 25 and 10 mg both reduced mean insulin dose and body weight over 52 weeks (placebo‐corrected changes, −9 to −11 IU/day and −2.4 to −2.5 kg), without increasing the risk of hypoglycaemia.

Several other available oral fixed‐dose combinations contain immediate‐release metformin as one of the components and are usually taken twice daily, while the dual inhibitor combination therapy (SGLT2/DPP‐4) is taken once daily. Thus, this combination offers an advantage of reduced pill burden.

Conclusion {#ijcp12720-sec-0018}
==========

Dual inhibitor combination therapy (SGLT2/DPP‐4) with empagliflozin/linagliptin STCs has been investigated in drug‐naïve patients and in patients on metformin background therapy. After 24 weeks of treatment the mean reduction in HbA1c with the STCs ranged from −1.08% to −1.24%. The dapagliflozin and saxagliptin combination has also been studied in patients on metformin background therapy. Numerically, the mean change from baseline in HbA1c with the dapagliflozin and saxagliptin combination was slightly higher (−1.47%) than values obtained with both empagliflozin/linagliptin STCs, the difference might partly be because of a higher baseline HbA1c in the dapagliflozin and saxagliptin combination study population. In drug‐naïve patients, empagliflozin/linagliptin STCs significantly improved glycaemic control (HbA1c and FPG) compared with all respective monotreatments except empagliflozin 25 mg, whereas with metformin co‐therapy, the STCs significantly improved glycaemic control relative to all respective mono‐treatments. Empagliflozin/linagliptin STCs achieved statistically significant mean differences in body weight reduction compared with linagliptin but not empagliflozin mono‐treatments in both the studies. In drug‐naïve patients, SBP and DBP changes did not alter significantly between the treatment groups, but in patients taking metformin, SBP and DBP were significantly lower with the STCs than with linagliptin mono‐treatment. Empagliflozin/linagliptin STCs were well‐tolerated with low rates of hypoglycaemia. Incidences of hypoglycaemia, events consistent with UTIs and genital infection with the STCs, occurred at similar frequencies compared with respective mono‐treatments. In patients with T2DM in need of a dual or triple therapy, dual inhibitor combination therapy appears to be an important option as an initial therapy, or additional therapy when metformin alone is not sufficient or suitable.

The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The author received no direct compensation related to the development of the manuscript. Writing assistance was provided by Radha Narayan, PhD, of Envision Scientific Solutions, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.
